Novartis likely to face Gilenya bribery allegations again
Novartis has to face the Gilenya bribery allegations again
Keystone-SDA
Select your language
Generated with artificial intelligence.
Listening: Novartis likely to face Gilenya bribery allegations again
The Swiss pharmaceutical company Novartis will probably have to face up to the allegations of a whistleblower regarding the sale of the multiple sclerosis drug Gilenya. According to Reuters, the 2nd Court of Appeals in Manhattan, New York, made the decision on Friday.
This content was published on
2 minutes
Keystone-SDA
Deutsch
de
Novartis muss sich erneut den Gilenya-Schmiergeld-Vorwürfen stellen
Original
The pharmaceutical company headquartered in Basel is accused of making so-called kickback payments to doctors to promote Gilenya to patients. According to the allegation, Novartis violated the federal False Claims Act by holding fictitious lecture events to promote the sale of Gilenya.
The case was triggered by former Novartis representative Stephen Camburn. He claims that Novartis paid doctors thousands of dollars and invited them to dinners in upscale restaurants to appear at the events. In this way, state health insurers such as Medicare were defrauded, the report continued.
Friday’s decision by the Court of Appeals reversed a September 2022 dismissal of the lawsuit by a US District Court in Manhattan and sent the case back to that court. Camburn had already sued Novartis in May 2013, and his allegations were dismissed by a court for the first time in spring 2020.
More
More
Whatever happened to the world’s most expensive drug?
This content was published on
Swiss pharma giant Novartis launched Zolgensma five years ago with a price tag of $2.1 million. What happened to it?
Novartis has not yet commented on the latest developments in this whistleblower case. The multiple sclerosis drug Gilenya remains one of the most important sales drivers for Novartis. In 2023, the Group generated global sales of just under one billion US dollars with it, out of total sales of $45.4 billion. However, Gilenya sales have declined significantly compared to previous years.
Adapted from German by DeepL/ac
This news story has been written and carefully fact-checked by an external editorial team. At SWI swissinfo.ch we select the most relevant news for an international audience and use automatic translation tools such as DeepL to translate it into English. Providing you with automatically translated news gives us the time to write more in-depth articles.
If you want to know more about how we work, have a look here, if you want to learn more about how we use technology, click here, and if you have feedback on this news story please write to english@swissinfo.ch.
Popular Stories
More
Banking & Fintech
UBS releases ‘hundreds’ of staff in fresh wave of job cuts
Should Switzerland take measures to support its struggling industries?
Industrial policies are back in fashion, not only in the United States but also in the EU. Should Switzerland, where various industries are struggling, draw inspiration from such policies?
UBS has cut 10,000 jobs since Credit Suisse takeover in 2023
This content was published on
UBS Group has cut more than 10,000 roles since it bought Credit Suisse, marking a milestone in the lender’s efforts to integrate its former rival.
Swiss multinational SGS to move HQ from Geneva to Zug
This content was published on
The Swiss multinational SGS, the world’s leading testing, inspection and certification company, plans to move its headquarters from Geneva to canton Zug in central Switzerland.
Swiss army takes part in international tank competition
This content was published on
Around 20 Swiss army personnel and two Leopard 2 tanks are taking part in an international tank competition in Grafenwöhr, Germany, this week.
Omega-3 supplements seem to slow ageing process, Swiss study finds
This content was published on
Taking a daily omega-3 supplement appears to slow down the rate of biological ageing by up to four months, according to a study by researchers at the University of Zurich.
This content was published on
The Swiss writer and translator Alain Claude Sulzer has been awarded the Solothurn Literary Days Prize 2025 for his lifetime's work.
Prix de Lausanne features 85 dancers from 23 countries
This content was published on
The 53rd Prix de Lausanne international ballet competition is underway. A total of 85 young dancers from 23 countries are competing in the Swiss city.
Swiss Solidarity charity collected CHF34 million in 2024
This content was published on
Swiss Solidarity, the humanitarian arm of the Swiss Broadcasting Corporation (SBC), raised CHF34.4 million ($37.7 million) in donations in 2024 and spent CHF63 million on humanitarian projects.
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.